FemRx' Opera Star cleared for US marketing
This article was originally published in Clinica
Executive Summary
Gynaecology specialist FemRx has received 510(k) clearance for its minimally invasive alternative to hysterectomy, the Opera Star system. The Out-Patient Endometrial Resection/Ablation device treats abnormal uterine bleeding in most patients without the need for an incision (see Clinica No 696, p 10). The system consists of a Specialised Tissue Aspirating Resectoscope which enables gynaecological surgeons to resect and ablate the endometrial lining and remove fibroids while continuously aspirating tissue for pathological evaluation.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.